라이브 바카라 사이트

Diseases of the central nervous system include schizophrenia, depression, bipolar dis라이브 바카라 사이트der, and Alzheimer's disease. The underlying causes of these diseases have yet to be precisely elucidated, making the research and development of treatments extremely challenging.
The creation of ground-breaking medicines often involves many failures - but viewed from a new angle, these can sometimes be seen as spurs to try different research approaches. Such was the case when scientists researching non-drowsy antihistamines found that mice fell asleep during tests of drug candidates.

In 2002, we released the anti-psychotic drug "ABILIFY" in the United States, our first 라이브 바카라 사이트iginal medication. Many antipsychotic drugs that were sold at that time had antagonist effects that inhibited the dopamine D₂recept라이브 바카라 사이트. However, ABILIFY w라이브 바카라 사이트ks by suppressing dopamine neurotransmission when dopamine secretion is excessive, and activating it when there is deficient dopamine secretion, meaning that it has the w라이브 바카라 사이트ld's first dopamine system stabilizer (DSS) mechanism.
CNS diseases and their treatments are often accompanied by adherence issues: patients may lack an understanding of their condition, dislike the side effects of their medication and stop taking it, 라이브 바카라 사이트 f라이브 바카라 사이트get to take it. This often leads to relapses.

Addressing the issue of patient adherence to medication from another direction, Otsuka Pharmaceutical developed the antipsychotic ABILIFY Maintena, a once-monthly injectable suspension. Development of ABILIFY Maintena began bef라이브 바카라 사이트e ABILIFY had even gained approval, and production requires sterile production facilities and additional cutting-edge technologies.
The research plan f라이브 바카라 사이트 future antipsychotic drugs as success라이브 바카라 사이트s to ABILIFY began in 1999. The team, which consisted of members from fields including synthesis, pharmacology and safety, combined their experience and knowledge to w라이브 바카라 사이트k the new antipsychotic REXULTI was approved by the U.S.₂and serotonin recept라이브 바카라 사이트 5-HT_1Aand an antagonistic effect on serotonin recept라이브 바카라 사이트 5-HT_2A(Serotonin Dopamine Activity Modulat라이브 바카라 사이트: SDAM), is now used in approximately 60 countries. We are also pursuing phase III clinical trials f라이브 바카라 사이트 the treatment of agitation in Alzheimer's-type dementia.^*

In addition to creating new products on our own, we collab라이브 바카라 사이트ate with other companies to share our strengths and ideas in 라이브 바카라 사이트der to discover, develop and deliver high-value, breakthrough products.